



Express Mail Label No. ER620044979US

PATENT APPLICATION
Docket No.: 51271/33 US
AV-1023.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Allen

Serial No.: 10/056,788

Filed: January 23, 2002

For: MUSCLE DIRECTED GENE TRANSFER BY USE OF
RECOMBINANT AAV-1 AND AAV-6 VIRIONS

Examiner: Brian A. Whiteman

)
)
)
)
) Art Unit
) 1635
)
)
)
)
)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

TO THE COMMISSIONER FOR PATENTS:

1. Pursuant to the duty of disclosure, documents listed on the accompanying Form PTO-1449 (or equivalent) are presented for the Examiner's consideration.

- ☒ Copies of listed documents are enclosed. (37 CFR § 1.98(a))
- ☐ Copies of listed U.S. patent documents are omitted because this application was filed after June 30, 2003 and is, thus, subject to image file wrapper processing. Copies of listed foreign patent documents and non-patent literature are enclosed.
- ☐ Copies of the documents listed on sheet(s) _____ of Form PTO-1449 (or equivalent) are omitted because (1) they are already of record in U.S. Patent Application No. _____, filed _____, on which this application relies for an earlier filing date under 35 U.S.C. § 120; and (2) any information disclosure statement filed in the prosecution of Application No. _____, complies with 37 CFR §§ 1.98(a) through (c). (37 C.F.R. § 1.98(d))

2. ☐ The Examiner's attention is directed to the enclosed copy of copending U.S. Patent Application No. _____, filed _____, for _____, which is cited in this application.

05/11/2004 DEMMANU1 00000074 10056788

03 FC:1806

180.00 0P

3. This information disclosure statement is being submitted (check box a., b., or c.):
- a. ☐ Within three months of the filing date of a national application or entry of the national stage in an international application; or before the mailing of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114. (No statement under 37 CFR 1.97(e) is required.); or
 - b. ☒ After the period set forth in paragraph 3a, but before the mailing date of either a final action, a notice of allowance, or an action that otherwise closes prosecution in the application. (Check box i. or ii.)
 - i. ☒ A \$180.00 information disclosure statement submission fee set forth in 37 CFR 1.17(p) is enclosed, or
 - ii. ☐ A statement specified by 37 CFR 1.97(e) is set forth below; or
 - c. ☐ After the mailing date of a final action or notice of allowance and on or before payment of the issue fee. A statement specified by 37 CFR 1.97(e) is set forth below. Enclosed is a \$180.00 information disclosure statement processing fee set forth in 37 CFR 1.17(p).
4. If a statement specified by 37 CFR 1.97(e) is required, the attorney or agent signing below hereby states that:
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - ☐ no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.

5. ☐ A concise explanation of the relevance of each document not in the English language and/or selected documents in the English language is set forth below.

DATED this ____ day of May, 2004.


Respectfully submitted,



Mara K. Featherstone
Registration No. 50,390

STOEL RIVES LLP
One Utah Center
201 South Main Street, Suite 1100
Salt Lake City, UT 84111
Telephone: (801) 578-6932
Facsimile: (801) 578-6999

CUSTOMER NO. 35735



PTO-FORM 1449

Sheet 1 of 1

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
51271/33 US
(Avigen Ref. 1023.US)APPLICATION NO.
10/056,788Title: MUSCLE DIRECTED GENE TRANSFER BY USE OF
RECOMBINANT AAV-1 AND AAV-6 VIRIONS

APPLICANT – Allen

Art Unit: 1635

FILING DATE-
January 23, 2002EXAMINER
Brian A. Whiteman

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	6,221,349	Apr. 24, 2001	Couto et al.	A61K	35/00	Jul. 30, 1999

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication, etc.)

2	Flotte et al., Clinical Protocol "Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults, <i>Human Gene Therapy</i> 14:93-128 (2004).
3	Song et al., Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice, <i>Gene Therapy</i> (2004).
4	Mochizuki et al., Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice, <i>Gene Therapy</i> (2004).
5	Galeano et al., Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse, <i>Diabetologia</i> (2003).
6	Tsai et al., Gene treatment of cerebral stroke by rAAV vector delivering IL-1ra in a rat model, <i>Molecular Neuroscience, NeuroReport</i> (2003).
7	Skorupa et al., Sustained Production of β -Glucuronidase from Localized Sites after AAV Vector Gene Transfer Results in Widespread Distribution of Enzyme and Reversal of Lysosomal Storage Lesions in a Large Volume of Brain in Mucopolysaccharidosis VII Mice, <i>Experimental Neurology</i> (1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CUSTOMER NO. 35735

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
51271/33

In Re Application Of: **Allen**


Serial No.
10/056,788

Filing Date
January 23, 2002

Examiner
Brian A. Whiteman

Group Art Unit
1635

Title: **MUSCLE DIRECTED GENE TRANSFER BY USE OF RECOMBINANT AAV-1 AND AAV-6 VIRIONS**



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☒ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 51271/33
In Re Application: Allen			
Serial No. 10/056,788	Filing Date January 23, 2002	Examiner Brian A. Whiteman	Group Art Unit 1635
MUSCLE DIRECTED GENE TRANSFER BY USE OF RECOMBINANT AAV-1 AND AAV-6			
<div style="text-align: center;"> Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) </div> <p> <input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. 50-2375 as described below. </p> <div style="display: flex; justify-content: space-between;"> <div> <input type="checkbox"/> Charge the amount of _____ <input checked="" type="checkbox"/> Credit any overpayment. <input checked="" type="checkbox"/> Charge any additional fee required. </div> <div> <input checked="" type="checkbox"/> USPTO Credit Card Form 2038 - \$180 </div> </div> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <div style="width: 45%;"> <p style="text-align: center;">Certificate of Transmission by Facsimile*</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F: </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> _____ (Date) </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="text-align: center;">Signature</div> </div> <div style="border: 1px solid black; padding: 5px;"> <div style="text-align: center;">Typed or Printed Name of Person Signing Certificate</div> </div> </div> <div style="width: 45%;"> <p style="text-align: center;">Certificate of Mailing by First Class Mail</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> <div style="text-align: center;">Signature of Person Mailing Correspondence</div> </div> <div style="border: 1px solid black; padding: 5px;"> <div style="text-align: center;">Typed or Printed Name of Person Mailing Certificate</div> </div> </div> </div> <p style="margin-top: 10px;"> *This certificate may only be used if paying by deposit account. </p> <div style="display: flex; justify-content: space-between; margin-top: 10px;"> <div style="width: 45%;"> <p style="font-size: 1.2em; margin: 0;"> <div style="text-align: center; font-size: 0.8em;">Signature</div> </p> <p style="margin: 0;"> Mara K. Featherstone Registration No. 50,390 STOEL RIVES LLP One Utah Center 201 South Main Street, Suite 1100 Salt Lake City, Utah 84111 Tel: (801) 578-6992 Fax: (801) 578-6999 CC: </p> </div> <div style="width: 45%;"> <p style="margin: 0;"> Dated: <i>May 6, 2004</i> </p> </div> </div>			